Putative neuroprotective role of visfatin against cognitive dysfunction in obese patients by Bieliński, Maciej et al.
Volume : 3 | Issue : 12 | Dec 2014 ISSN - 2250-1991
149  | PARIPEX - INDIAN JOURNAL OF RESEARCH
Research Paper
Putative neuroprotective role of visfatin against 
cognitive dysfunction in obese patients
Physical Education
Maciej Bieliński Jan Biziel’s University Hospital, Division of Vascular Diseases and 
Internal Medicine, Bydgoszcz, Poland
Joanna Pulkowska-
Ulfig
Collegium Medicum of Nicolaus Copernicus University, Department 
of Clinical Neuropsychology, Bydgoszcz, Poland
Andrzej Tretyn
Nicolaus Copernicus University, Department of Biotechnology, 
Toruń, Poland
 Roman Junik
Collegium Medicum of Nicolaus Copernicus University, Nuclear 
Medicine Laboratory of the Department of Endocrinology and 
Diabetology, Bydgoszcz, Poland
Alina Borkowska
Collegium Medicum of Nicolaus Copernicus University, Depart-
ment of Clinical Neuropsychology, Bydgoszcz, Poland
Marcin Sikora
Nicolaus Copernicus University, Department of Biotechnology, Toruń, 
Poland
Ewa Kopczyńska
Collegium Medicum of Nicolaus Copernicus University, 
Department of Pathobiochemistry and Clinical Chemistry, 
Bydgoszcz, Poland
Anna Kamińska
Collegium Medicum of Nicolaus Copernicus University, Nuclear 
Medicine Laboratory of the Department of Endocrinology and 
Diabetology, Bydgoszcz, Poland
Marta Tomaszewska
Collegium Medicum of Nicolaus Copernicus University, Department 
of Clinical Neuropsychology, Bydgoszcz, Poland








Objectives: Visfatin (adipokine) is thought to have neuroprotective properties. The aims of to determine the type and extent 
of prefrontal cortical dysfunction and to evaluate the potential neuroprotective role of visfatin.
Methods: Sixty-one obese patients were included. A diagnosis of primary obesity was made on the basis of a BMI > 30. 
Visfatin serum levels were determined by enzyme immunoassay. The Wisconsin Card Sorting Test (WCST) was used to assess 
prefrontal cortex-mediated cognitive function. 
Results: Visfatin levels were not correlated with age or BMI. However, patients with higher visfatin levels tended to show 
an overall improvement in WCST scores. Nonetheless, a significant positive correlation (P = 0.032) was found only between 
high serum visfatin levels and the number of correctly completed categories in the WCST.
Discussion: The results described herein indicate a possible neuroprotective effect of visfatin against obesity-related cognition 
dysfunction, particularly in regard to the categorizing capacity associated with executive function. 
Introduction
Visfatin and metabolism
An intensive body of research on fatty tissue metabolism has 
revealed the adipocyte as a key player in the regulation of lip-
id and energy metabolism, as well as in the production and 
secretion of hormones and cytokines. These adipocyte-de-
rived modulatory factors are collectively termed  adipokines. 
Adipokines can exert both local and global hormonal actions, 
and include proteins such as adiponectin, interleukin-6, leptin, 
resistin, tumour necrosis factor-alpha, and visfatin. Adipokines 
also play major roles in the pathogenesis of insulin-resistant 
and cardiovascular diseases (Sommer et al. 2008).
Visfatin is a 52-kDa protein encoded by a gene contained 
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within the long arm of chromosome 7 between 7q21.1 and 
7q31.33 (Jia et al. 2004). Visfatin was initially known as pre-
B-cell colony-enhancing factor (PBEF), because of its ability 
to induce the maturation of B lymphocytes, or nicotinamide 
phosphoribosyltransferase (Nampt), because of its activity 
during the biosynthesis of nicotinamide adenine dinucleotide 
(NAD) (Kamińska et al. 2010). The production of nicotinamide 
adenine mononucleotide (NMN) by PBEF/Nampt/visfatin is the 
rate-limiting step in the salvage pathway for the subsequent 
biosynthesis of NAD by NMN adenylyltransferase. NAD is in 
turn an essential coenzyme involved in redox reactions during 
intracellular energy metabolism (Revollo et al. 2007). 
In addition to its participation in energy metabolism, visfatin 
can reportedly mimic the actions of insulin by binding to and 
activating the insulin receptor. Indeed, visfatin lowered plasma 
glucose levels in mice, presumably by substituting for insulin 
(Fukuhara el a. 2005). These findings suggest the potential 
therapeutic utility of visfatin in the management of diabetes 
and other metabolic disorders.
Regulation of visfatin production is dependent on the stimula-
tion of macrophages in fatty tissue (Mayi et al. 2010). There-
fore, inflammatory processes are crucial for normal visfatin 
metabolism. At the same time,  visfatin contributes to vascu-
lar inflammation by mediating pro-inflammatory signalling in 
the blood vessel wall (Romacho et al. 2009). The adipokine 
also affects vascular reactivity by triggering endothelium-de-
pendent, nitric oxide-related vasodilatation (Yamawaki et al. 
2009). Accordingly, visfatin could theoretically modify the 
course of metabolic syndrome.
Visfatin and neuroprotection
Several lines of evidence suggest that visfatin operates in the 
central nervous system as a neuroprotective factor. For ex-
ample, genetically altered mice with reduced visfatin/PBEF/
Nampt expression had a significantly larger infarct volume and 
a higher number of degenerating neurons than age-matched, 
wild-type controls in a photothrombosis-provoked model of 
cerebral ischemia (Zhang et al. 2010). These observations indi-
cate that visfatin limited neuronal damage after stroke, prob-
ably by enhancing energy metabolism (Zhang et al. 2010) and 
promoting blood vessel relaxation (Yamawaki et al. 2009). 
Furthermore, a significantly higher serum visfatin level was 
observed among human patients with ischemic stroke relative 
to control subjects without stroke. The elevated visfatin levels 
were independently associated with stroke occurrence, imply-
ing that the adipokine was upregulated in an attempt to pro-
tect the brain from further injury (Lu et al. 2009).
Cognitive dysfunction in obesity, and putative neuroprotective 
effect of visfatin
Several reports have suggested that cognitive abilities can be 
adversely affected in obese subjects, especially in terms of 
working memory and executive function (Chelune et al. 1986; 
Gunstad et al. 2007; Lokken et al. 2009). Executive function 
refers to a set of mental processes utilized in goal achieve-
ment that allow the individual to integrate past experiences 
with present actions. Executive function and working memo-
ry are thought to be regulated by the prefrontal cortex. Con-
versely, executive dysfunction and cognitive defects in working 
memory are linked to abnormalities in prefrontal metabolic ac-
tivity and decreased local blood flow in the prefrontal cortex 
(Volkow et al. 2009; Willeumier et al. 2011).
Whitmer and Kivipelto observed numerous groups of obese 
and overweight patients over a period of more than 20 
years and found that a body mass index (BMI) of > 25 was 
an independentrisk factor for dementia (Kivipelto et al. 2005; 
Whitmer et al. 2005). Moreover, a study by Gustafson and 
colleagues indicated that elderly women with a BMI of > 25 
were more likely to develop Alzheimer’s disease than age-
matched, normal-weight women, likely due to the unfavour-
able impact of obesity on vascular health (Gustafson et al. 
2003).
In light of these findings, the current study sought to validate 
the relationship between cognitive dysfunction and obesity. 
We also explored the hypothesis that visfatin might confer 




Sixty-one Caucasian patients (48 women and 13 men; mean 
age, 39.9 ± 12.6 years) of Polish nationality with primary obe-
sity were enrolled in this study. Primary obesity was defined 
as a BMI of > 30, where secondary causes of obesity were 
excluded based on medical history, physical examination, and 
biochemical results (e.g., cortisol, prolactin, and thyroid-stim-
ulating hormone levels). Biometric analyses were performed 
to measure the weight (kg), height (m), waist and hip circum-
ferences (cm), BMI, and waist-to-hip ratio (WHR) for each pa-
tient. Subjects with a severe somatic or psychiatric disorder, 
any neurological abnormality, or any addiction to drugs or 
alcohol were excluded from the study. The demographic and 
clinical characteristics of the study participants are shown in 
Table 1. The Bioethics Committees of Collegium Medicum (By-
dgoszcz, Poland) and Nicolaus Copernicus University (Toruń, 
Poland) approved this study (agreement No. 533/2008). This 
study conformed to the guidelines of the Helsinki Declaration 
of 1975, as revised in 2000.
Table 1. Demographic and clinical characteristics of the 
study participants.















BMI, body mass index.
Measurement of serum visfatin content
Serum visfatin levels were determined via an enzyme immuno-
assay that employed a primary antibody against the C-termi-
nal region of human visfatin (Phoenix Pharmaceuticals, Inc., St. 
Joseph, MO, USA). Spearman’s rank-order correlation analysis 
was used to investigate the associations between serum visfa-
tin levels and demographic and clinical factors.
Neuropsychological assessment
A neuropsychological assessment was conducted for each 
study participant by using the computerized version of the 
Wisconsin Card Sorting Test (WCST). The WCST evaluates 
working memory and execution function connected with pre-
frontal cortical activity (Heaton et al. 1993). The original ver-
sion of the test was created by Berg and Grat in 1948 (Berg 
1948) to gauge abstract thinking and perseveration, the ability 
to change or maintain logical conceptions, and the capacity 
to properly use feedback information from the environment 
to make decisions. Five automatically calculated WCST pa-
rameters were used for neuropsychological assessment in the 
present investigation: 1) the percentage of perseverative errors 
(WCST_P), also known as A-not-B errors, reflecting an inability 
to change a reaction when confronted with relevant stimuli; 
2) the percentage of non-perseverative errors (WCST_NP), re-
flecting random or accidental errors resulting from an atten-
tion deficit or the failure to inhibit distracting stimuli;  3) the 
percentage of conceptual level responses (WCST_CLR), reflect-
ing the ability to carry out conceptual thinking and strategic 
planning; 4) the number of correctly completed categories 
(WCST_CC), reflecting the ability to utilize new information 
along with previous experiences to achieve a goal; and 5) the 
number of cards required to complete the first category (WC-
ST_1st), reflecting the capacity to formulate a logical concep-
tion.
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Statistical analysis
The Shapiro-Wilk test was initially used to assess the normality 
of the distribution of the study variables. Because the Shap-
iro-Wilk test revealed a lack of normal distribution, the median 
and the range (minimum and maximum values) were instead 
used to compare study variables. The significance of differenc-
es between two groups was verified by using the non-para-
metric Mann-Whitney U test, and the significance of differ-
ences among three groups was verified by using the Kruskal 
Wallis analysis of variance (ANOVA) test. In all cases, a P value 
of < 0.05 was considered statistically significant. All calcula-
tions were performed by using the STATISTICA 9.0 Suite of 
Analytics Software Products and Solutions (StatSoft, Tulsa, OK, 
USA).
Results
Serum visfatin levels among the study participants were meas-
ured via an enzyme immunoassay with a primary antibody 
against the C-terminal region of visfatin. Median visfatin lev-
els were similar in age-matched women (45.6 ng/ml) and men 
(36.6 ng/ml) (Table 1). Correlations between serum visfatin 
concentrations and various demographic and clinical factors 
are shown in Table 2. Visfatin content was negatively, albeit 
insignificantly, associated with the age, waist circumference, 
and WHR of the subjects. However, visfatin content was not 
significantly correlated with BMI (Table 2).
Table 2. Spearman’s rank-order correlation analysis of as-
sociations
between serum visfatin levels and demographic/clinical 
factors.
Parameter R P value
Age −0.199 0.14
BMI 0.082 0.53
Waist circumference −0.058 0.65
WHR −0.193 0.14
R, Spearman’s correlation coefficient.
WHR, Waist-to-hip ratio.
In addition, serum visfatin levels were not significantly differ-
ent in patients with central (abdominal) vs. generalized (uni-
formly distributed) obesity, as assessed by the Mann Whitman 
U test (Table 3). 
Table 3. Serum visfatin levels in patients with 
central vs. generalized obesity. 
Obesity type N Median visfatin level, ng/ml (range)
Central 34 40.3 (4.1–331.5)
Generalized 27 48.2 (7.9–133.1)
Furthermore, no significant differences were found among pa-
tient groups with obesity grades I, II, and III, as determined by 
the Kruskal Wallis ANOVA test (Table 4). 
Table 4.  Serum visfatin levels in study participants 
according to obesity grade. 




Neuropsychological assessments were conducted for the entire 
study group via the WCST with the five parameters described 
above (WCST_P, WCST_NP, WCST_CLR, WCST_CC, and WC-
ST_1st). The relationship between serum visfatin levels and 
the five WCST parameters was then explored via Spearman’s 
rank-order correlation analysis (Table 5). A significant correla-
tion (P = 0.032) was found only between visfatin content and 
the number of correctly completed categories (regarded as a 
determinant of effective thinking and the ability to integrate 
previous experiences and environmental cues into appropri-
ate actions), but not between visfatin content and the other 
WCST parameters (Table 5). 
Table 5. Spearman rank-order correlation analysis 
of associations between serum visfatin levels and WCST 
scores.






R, Spearman’s correlation coefficient.
WCST, Wisconsin Card Sorting Test.
WCST_P, percentage of perseverative errors.
WCST_NP, percentage of non-perseverative errors.
WCST_CLR, percentage of conceptual level responses.
WCST_CC, number of correctly completed categories.
WCST_1st, number of cards needed to complete first category.
Patients were then stratified into two subgroups according to 
visfatin levels, low (< the median serum visfatin level for all 
subjects) vs. high (> the median serum visfatin level for all 
subjects) (Table 6). Patients in the high-visfatin subgroup tend-
ed to show an overall improvement in WCST scores. Neverthe-
less, a significant correlation (P = 0.039) was again found only 
between serum visfatin content and the number of correctly 
completed categories (Table 6).
Table 6. WCST scores in subgroups  stratified by low and 
high serum visfatin levels.
WCST 
parameter
Low visfatin level 
(< 51.6 ng/ml) 
N = 40
 median (range)





WCST_P 9.0 (5–58) 9.0 (5–17) 0.57
WCST_NP 12.5 (3–51) 8.0 (4–27) 0.22
WCST_CLR 73.0 (9–91) 79.0 (50–90) 0.29
WCST_CC 6.0 (0–6) 6.0 (2–6) 0.039
WCST_1st 11.5 (10–129) 11.0 (10–63) 0.72
WCST, Wisconsin Card Sorting Test.
WCST_P, percentage of perseverative errors.
WCST_NP, percentage of non-perseverative errors.
WCST_CLR, percentage of conceptual level responses.
WCST_CC, number of correctly completed categories.
WCST_1st, number of cards needed to complete first category.
Discussion
Roles of visfatin
Visfatin is an adipocyte-derived enzyme that can reduce serum 
glucose levels in mice by binding to the insulin receptor and 
mimicking the actions of insulin (Fukuhara et al. 2005). Vis-
fatin is also implicated in nitric oxide-related vasodilatation in 
endothelium-intact rat aorta through actions on endothelial 
nitric oxide synthase  Yamawaki et al. 2009). Moreover, recent 
publications have underscored a potential neuroprotective role 
of visfatin during ischemic responses in the central nervous 
system, which apparently stems from the capacity of the adi-
pokine to enhance energy metabolism and to induce endothe-
lium-dependent blood vessel relaxation (Yamawaki et al. 2009; 
Zhang et al. 2010). 
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Visfatin and inflammation
A recent study scrutinized the connection between circulat-
ing visfatin levels and gene expression in visceral and subcu-
taneous fat. The investigators found that visfatin levels were 
higher in obese compared with normal subjects, and that the 
elevated visfatin content was strongly associated with the ex-
pression of pro-inflammatory factors in fatty tissue (Terra et al. 
2011; Conde et al. 2011). Along the same lines, a recent re-
view highlighted the role of adipose tissue as an endocrine/
paracrine/autocrine organ, and stressed the role of visfatin 
and other adipokines in the physiopathology of a number of 
inflammatory diseases (Conde et al. 2011). Therefore, these 
reports imply that high visfatin levels in obese subjects may 
contribute to the development of harmful inflammatory condi-
tions Terra et al. 2011; Conde et al. 2011), such as alterations 
in immunity and chronic low-grade inflammation.
Visfatin and cognitive function
The analyses performed in the current investigation revealed 
a significant positive correlation between serum visfatin lev-
els and the number of correctly completed categories in the 
WCST, which is widely used to assess prefrontal cortex-de-
pendent cognitive function. The number of correctly complet-
ed categories in the WCST (the WCST_CC score) provides an 
index of thinking effectiveness, suggesting a neuroprotective 
advantage of high visfatin levels in obese subjects. The rela-
tionship between visfatin levels and the WCST_CC score was 
confirmed in a subgroup analysis of patients with low and 
high serum visfatin content. 
Conclusions
In conclusion, the current study suggests that visfatin might 
have a protective effect on nervous tissue in the prefrontal 
cortex of obese individuals. However, obesity is a complex 
medical condition with a multi-faceted etiology, and many 
abnormal processes can affect the prefrontal cortex. Moreo-
ver, visfatin may contribute to both detrimental and beneficial 
biological processes in obese subjects. Further investigation is 
required to clarify the neuroprotective role of visfatin.
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